Cytoreduction and intraperitoneal heated chemotherapy for the treatment of endometrial carcinoma recurrent within the peritoneal cavity

International Journal of Gynecological Cancer

Volumn 17, Issue 1, 2007, Pages 204-209

  Helm, C W ^a,c   Toler, C R ^a   Martin III, R S ^b   Gordinier, M E ^a   Parker, L P ^a   Metzinger, D S ^a   Edwards, R P ^a  

^a UNIVERSITY OF LOUISVILLE SCHOOL OF MEDICINE   (United States)

^b University of Louisville School of Medicine   (United States)

^c James Graham Brown Cancer Center   (United States)

Author keywords

Cisplatin; Hyperthermia; Intraperitoneal chemotherapy; IPHC; Recurrent endometrial cancer

Indexed keywords

CISPLATIN; CREATININE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CREATININE BLOOD LEVEL; DATA ANALYSIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM CELL; EXPERIENCE; FEMALE; FOLLOW UP; HISTOLOGY; HOSPITALIZATION; HUMAN; HUMAN TISSUE; HYPERTHERMIC THERAPY; LAPAROTOMY; MEDICAL RECORD REVIEW; PERITONEAL CAVITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; SEPTICEMIA; TREATMENT DURATION; WOUND INFECTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, ENDOMETRIOID; CISPLATIN; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYPERTHERMIA, INDUCED; INFUSIONS, PARENTERAL; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PERITONEAL NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33846873447     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2006.00751.x     Document Type: Article

References (48)

1. American Cancer Society. Cancer facts and figures 2005. Atlanta, GA: American Cancer Society, 2005.
2. Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet 2003;1:79-118.
3. Fleming GF, Filiaci VL, Bentley RC et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study [see comment]. Ann Oncol 2004;15:1173-8.
4. Kuten A, Grigsby PW, Perez CA, Fineberg B, Garcia DM, Simpson JR. Results of radiotherapy in recurrent endometrial carcinoma: a retrospective analysis of 51 patients. Int J Radiat Oncol Biol Phys 1989;17:29-34.
5. Barakat R, Grigsby PW, Sabbatini P, Zaino RJ. Corpus: epithelial tumors. In: Hoskins WJ, Perez CA, Young RC, eds. Principles and practice of gynecologic oncology. Philadelphia, PA: Lippincott Williams and Wilkins, 2000:919-79.
6. Alberts DS, Liu PY, Hannigan EV et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [see comment]. N Engl J Med 1996;335:1950-5.
7. Markman M, Bundy BN, Alberts DS et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group [see comment]. J Clin Oncol 2001;19:1001-7.
8. Armstrong DD, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34-43.
9. Giovanella BC, Stehlin JS Jr, Morgan AC. Selective lethal effect of supranormal temperatures on human neoplastic cells. Cancer Res 1976;36(Pt 1):3944-50.
10. Hahn GM. Potential for therapy of drugs and hyperthermia. Cancer Res 1979;39(Pt 2):2264-8.
11. Meyn RE, Corry PM, Fletcher SE, Demetriades M. Thermal enhancement of DNA damage in mammalian cells treated with cis-diamminedichloroplatinum(II). Cancer Res 1980;40:1136-9.
12. Alberts DS, Peng YM, Chen HS, Moon TE, Cetas TC, Hoeschele JD. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J Natl Cancer Inst 1980;65:455-61.
13. Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 1994;69:235-41.
14. Akaboshi M, Tanaka Y, Kawai K, Akuta K, Masunaga S, Ono K. Effect of hyperthermia on the number of platinum atoms binding to DNA of HeLa cells treated with 195mPt-radiolabelled cis-diaminedichloroplatinum(II). Int J Radiat Biol 1994;66:215-20.
15. Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003;10:463-8.
16. Herman TS, Teicher BA, Cathcart KN, Kaufmann ME, Lee JB, Lee MH. Effect of hyperthermia on cis-diamminedichloroplatinum(II) (rhodamine 123)2[tetrachloroplatinum(II)] in a human squamous cell carcinoma line and a cis-diamminedichloroplatinum(II)-resistant subline. Cancer Res 1988;48:5101-5.
17. Fujimoto S, Takahashi M, Mutou T et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 1997;79:884-91.
18. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR, Levine EA. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001;67:999-1003.
19. Sugarbaker PH, Chang D. Results of treatment of 385 patients with peritoneal surface spread of appendiceal malignancy. Ann Surg Oncol 1999;6:727-31.
20. Bartlett DL, Buell JF, Libutti SK et al. A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis [erratum appears in Cancer 1998;83:2241]. Cancer 1998;83:1251-61.
21. Loggie BW, Sterchi JM, Rogers AT et al. Intraperitoneal hyperthermic chemotherapy for advanced gastrointestinal and ovarian cancers. Reg Cancer Treat 1994;2:78-81.
22. Cavaliere F, Perri P, Di Filippo F et al. Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol 2000;74:41-4.
23. van der Vange N, van Goethem AR, Zoetmulder FA et al. Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot. Eur J Surg Oncol 2000;26:663-8.
24. Deraco M, Rossi CR, Pennacchioli E et al. Cytoreductive surgery followed by intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase II clinical study. Tumori 2001;87:120-6.
25. Panteix G, Beaujard A, Garbit F et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res 2002;22:1329-36.
26. Helm CW, Martin RS, Metzinger DS, Edwards RP. Secondary surgical cytoreduction and hyperthermic intraperitoneal chemotherapy for recurrent ovarian and endometrial cancer. International Gynecologic Cancer Society 2004;14(Suppl. 1):167.
27. Zanon C, Clara R, Chiappino I et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 2004;28:1040-5.
28. Reichman TW, Cracchiolo B, Sama J et al. Cytoreductive surgery and intraoperative hyperthermic chemoperfusion for advanced ovarian carcinoma. J Surg Oncol 2005;90:51-6.
29. Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2004;14:35-41.
30. Steller MA, Egorin MJ, Trimble EL et al. A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer [erratum appears in Cancer Chemother Pharmacol 1999;44:90]. Cancer Chemother Pharmacol 1999;43:106-14.
31. Witkamp AJ, de Bree E, Kaag MM et al. Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 2001;37:979-84.
32. National Cancer Institute: Cancer Therapy Evaluation Program common terminology criteria for adverse events v3.0. Available at: http://ctep.cancer. gov/forms/CTCAEv3.pdf
33. Lin LL, Grigsby PW, Powell MA, Mutch DG. Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer. Int J Radiat Oncol Biol Phys 2005;63:500-04.
34. Thigpen JT, Brady MF, Homesley HD et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004;22:3902-8.
35. Levine DA, Hoskins WJ. Update in the management of endometrial cancer. Cancer J 2002;8(Suppl. 1):31-40.
36. Price FV, Edwards RP, Kelley JL, Kunschner AJ, Hart LA. A trial of outpatient paclitaxel and carboplatin for advanced, recurrent and histologic high-risk endometrial carcinoma: preliminary report. Semin Oncol 1997;24:S15-78-82.
37. Hoskins PJ, Swenerton KD, Pike JA et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001;19:4048-53.
38. Scudder SA, Liu PY, Wilczynski SP et al. Paclitaxel and carboplatin with amifostine in advanced, recurrent, or refractory endometrial adenocarcinoma: a phase II study of the Southwest Oncology Group. Gynecologic Oncology 2005;96:610-5.
39. Thigpen JT, Blessing JA, Hatch KD, Barrett R, Adelson M, DiSaia PJ. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma. J Clin Oncol 1999;17:1736-44.
40. Lentz SS, Brady MF, Major FJ, Reid GC, Soper JT. A phase II trial of high dose megestrol acetate (Megace) in advanced or recurrent endometrial carcinoma. J Clin Oncol 1996;14:357-61.
41. McMeekin DS, Gordon A, Fowler J et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecologic Oncology 2003;90:64-9.
42. Fiorica JV, Brunetto VL, Hanjani P et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study [see comment]. Gynecologic Oncology 2004;92:10-4.
43. Markman M. Hormonal therapy of endometrial cancer. Eur J Cancer 2005;41:673-5.
44. Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP. Pelvic exenteration for recurrent endometrial cancer. Gynecologic Oncology 1999;75:99-102.
45. Morris M, Alvarez RD, Kinney WK, Wilson TO. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecologic Oncology 1996;60:288-91.
46. Aalders JG, Abeler V, Kolstad P. Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients. Gynecologic Oncology 1984;17:85-103.
47. Scarabelli C, Campagnutta E, Giorda G et al. Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma. Gynecologic Oncology 1998;70:90-3.
48. van de Vaart PJ, van der Vange N, Zoetmulder FA et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998;34:148-54.